Showing 1481-1490 of 8882 results for "".
Cosmeceutical Options
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmeceutical-options/18208/As the cosmeceutical market continues to grow, Nancy Samolitis, MD highlights one of her favorite options to support skin health.Cosmetic Boot Camp 2018 Presenter Insight
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-boot-camp-2018-presenter-insight/18290/Get up to date on Cosmetic Bootcamp. Presenters provide updates on microneedling, radiofrequency devices, lasers, fillers, neurotoxins, and more. The Cosmetic Bootcamp® provides training and educational opportunities for aesthetic medicine physicians and their staff. Hear from: Mary Lupo, MD; Vic NaEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andTalking to Patients: Men v. Women
https://practicaldermatology.com/topics/practice-management/talking-to-patients-men-v-women/18693/Every patient is unique, but aesthetic physicians may need to tailor their communication style based on the patient's sex. It's also essential to convey to men that you understand the male aesthetic and how their treatment goals may differ from the typical woman's.Galderma's Differin Goes OTC, CoolSculpting Approved for Upper Arms, ZO Skin Acquires ReFissa
https://practicaldermatology.com/series/dermwire-tv/galderma-s-differin-goes-otc-coolsculpting-approved-for-upper-arms-zo-skin-acquires-refissa/18549/Galderma's Differin Gel formulation of adapalene 0.1% is now available over the counter at major retail and drug stores in the US. ZELTIQ® Aesthetics' CoolSculpting is now FDA-cleared for fat reduction in the upper arms. ZO Skin Health has acquired the worldwide rights to ReFissa from Suneva MedicalHumphries to Valeant, Restylane Line Expands, 2016 Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-humphries-to-valeant-restylane-line-expands-2016-highlights/18709/The filler market in the US expands with FDA approval of Galderma's Restylane Refyne and Restalyne Define for the treatment of nasolabial folds in patients over the age of 21. The gels are manufactured with XpresHAn Technology, which allows a range of flexibility and support for varied patient needsTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?Improve Your Practice: Creating Innovation
https://practicaldermatology.com/topics/practice-management/improve-your-practice-creating-innovation/18649/Kathryn Schwarzenberger, MD and Tammie Ferringer, MD sat down with host Neal Bhatia, MD to discuss creativity and innovation in medicine. Based on a session they presented at the American Academy of Dermatology Annual Meeting, they offer tips for leaving time in your day to think about what you're dOvercoming Challenges in Topical Psoriasis Care
https://practicaldermatology.com/topics/psoriasis/overcoming-challenges-in-topical-psoriasis-care/18685/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for palmar plantar psoriasis and the combined use of topical corticosteroids with phototherapy. They also address alternative topical agents like topical immunomodulators.Restylane Silk Launches; Xeljanz to FDA
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-restylane-silk-launches-xeljanz-to-fda/18970/This edition of DermWireTV covers the launch of Restylane Silk from Galderma for the treatment of lips and FDA acceptance of the NDA for Pfizer's Xeljanz (tofacitinib) for adults with psoriasis. Plus, new data from the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) show incr